Table 2: Comparing demographic and clinical profile of
patients with remission, relapse and continuing proteinuria (Year 1 to 6).
|
|
Remission (x) n = 43 |
Relapse (y)
n = 44 |
Continuing
Proteinuria (z) n = 67 |
p value |
|
Sex
(F : M) |
25:18 |
30:21 |
46:21 |
0.499 |
|
Count
(%) |
58%:42% |
61%:39% |
69%:31% |
|
|
Age
at Diagnosis (Years) |
57
± 10 |
53 ± 11 |
49 ± 10 |
0.003 |
|
Total
Duration of Follow-up (Months) |
74
± 3 |
74
± 2 |
73
± 2 |
0.013 |
|
Hypertension
(Yes : No) |
16 (37%) |
21 (48%) |
35 (52%) |
0.301 |
|
EGFR (ml/min) |
||||
|
Year 0 |
47 ± 11 |
45 ± 10 |
51 ± 15 |
0.187 |
|
Year 6 |
42 ± 14 |
42 ± 13 |
47 ± 18 |
0.359 |
|
|
(p < 0.001) |
(p = 0.012) |
(p
< 0.001) |
|
|
Urinary
Protein (gm/day) |
||||
|
Year
0 |
0.9
± 0.6 |
1.1
± 0.7 |
1.6
± 0.5 |
<
0.001 |
|
Year
6 |
0.2
± 0.2 |
0.5
± 0.4 |
0.5
± 0.5 |
<
0.001 |
|
|
(p
< 0.001) |
(p
< 0.001) |
(p
< 0.001) |
|
|
Blood
Pressure (mmHg) |
||||
|
Systolic,
Year 1 |
137
± 12 |
136
± 12 |
132
± 12 |
0.086 |
|
Systolic,
Year 6 |
131
± 10 |
129
± 8 |
130
± 9 |
0.758 |
|
|
(p
= 0.013) |
(p
= 0.002) |
(p
= 0.116) |
|
|
Diastolic,
Year 1 |
88
± 5 |
86
± 7 |
84
± 8 |
0.137 |
|
Diastolic,
Year 6 |
81
± 6 |
81
± 6 |
82
± 5 |
0.304 |
|
|
(p
< 0.001) |
(p
= 0.002) |
(p
= 0.010) |
|
|
Arm
previously allocated to: |
||||
|
Aliskiren alone |
15
(35%) |
15
(34%) |
22
(33%) |
0.043 |
|
Losartan
alone |
12
(28%) |
9
(21%) |
30
(45%) |
|
|
Combined
Aliskiren and Losartan |
16
(37%) |
20
(45%) |
15
(22%) |
|